https://www.selleckchem.com/pr....oducts/anacetrapib-m
Immune checkpoint inhibitors (ICIs), by unleashing the anticancer response of the immune system, can improve survival of patients affected by several malignancies, but may trigger a broad spectrum of adverse events, including autoimmune hypophysitis. ICI-related hypophysitis mainly manifests with anterior hypopituitarism, while the simultaneous involvement of both anterior and posterior pituitary (i.e., panhypophysitis) has rarely been described. In June 2015, a 64-year-old man affected by liver metastases of a uveal melanom
Like
Comment
Share
